Premium
HIGH RATE OF MORBID CENTRAL LINE ASSOCIATED COMPLICATIONS DURING TREATMENT WITH DOSE‐ADJUSTED R‐EPOCH THERAPY FOR NON‐HODGKIN LYMPHOMA
Author(s) -
Reagan P.,
David R.,
Baran A.,
Kelly J.,
Loh K.,
Casulo C.,
Barr P.,
Friedberg J.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_193
Subject(s) - medicine , epoch (astronomy) , vincristine , population , rituximab , surgery , prednisone , clinical endpoint , regimen , gastroenterology , cyclophosphamide , chemotherapy , lymphoma , randomized controlled trial , stars , physics , environmental health , astronomy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom